Blocking Anti-Thyrotropin Receptor Antibodies Desensitize Cultured Human Thyroid Cells

Endocrinology ◽  
1988 ◽  
Vol 123 (4) ◽  
pp. 2062-2066 ◽  
Author(s):  
A. M. MADEC ◽  
S. CLAVEL ◽  
A. STEFANUTTI ◽  
J. ORGIAZZI
1995 ◽  
Vol 132 (1) ◽  
pp. 109-117 ◽  
Author(s):  
Ryo Takeuchi ◽  
Kanji Kasagi ◽  
Akinari Hidaka ◽  
Shinichi Miyamoto ◽  
Takashi Misaki ◽  
...  

Takeuchi R, Kasagi K, Hidaka A, Miyamoto S, Misaki T, lida Y, Konishi J. Augmentation of thyrotropin-induced iodide uptake in FRTL-5 cells by immunoglobulins containing blocking thyrotropin-receptor antibodies under NaCl-depleted conditions. Eur J Endocrinol 1995;132:109–17. ISSN 0804–4643 We have found recently that Graves' immunoglobulins (Igs) are more active under NaCl-free conditions to increase iodide uptake in FRTL-5 thyroid cells. The present study was designed to examine the effect of blocking-type thyrotropin (TSH)-receptor antibodies (TR-abs) in the same assay. FRTL-5 cells were incubated with crude Ig fractions from 13 patients with primary hypothyroidism having blocking TR-abs and 100 mU/l bovine TSH in NaCl-free Hanks' balanced salt solution (HBSS) supplemented with 274 mmol/l sucrose (HBBS(−)-sucrose to keep isotonicity for 3 days, followed by the determination of 60 min of 125I uptake in the cells. Thyrotropin alone increased the uptake to 3.3-to 5.2-fold of the basal. When the highest concentration (250 ml serum equivalent (eq.)/l) of the Ig was used, the TSH-stimulated 125I uptake was decreased to 0–42% in 11 of the 13 cases. When the lower concentrations (0.4–50 ml serum eq./l) were used, however, 125I uptake was enhanced (1.4- to 11.4-fold) unexpectedly in all 13 cases. Such an enhancement was specific to blocking TR-abs, because the effect was duplicated by the purified IgG but not by Igs from 10 healthy control subjects or from three TR-ab-negative hypothyroid patients. When Graves' Igs, instead of TSH, were used as a stimulator, the similar stimulatory effect of the Ig with blocking activity was observed on the 125I uptake induced by three Graves' Igs but not on the response to one Graves' Ig. These Igs alone displayed no stimulating activity. When isotonic 5H medium was used instead of HBSS(−)-sucrose, effects of these 13 Igs were only inhibitory on the TSH-stimulated 125I uptake. In summary, Igs containing blocking TR-abs from patients with primary hypothyroidism showed a variable effect on TSH- or Graves' Ig-induced 125I uptake, depending on their concentration and the presence of NaCl. Together with our recent reports that both stimulating and blocking TR-abs exist simultaneously in some patients, these observations suggest that the two types of TR-abs and TSH may play a more complicated role in disease expression than what has been suggested as merely a net activity. Kanji Kasagi, Department of Nuclear Medicine, Kyoto University School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-01, Japan


2003 ◽  
Vol 49 (8) ◽  
pp. 1402-1404 ◽  
Author(s):  
Carol M Preissner ◽  
Philip J Wolhuter ◽  
John W Sistrunk ◽  
Henry A Homburger ◽  
John C Morris

2014 ◽  
pp. 375-383 ◽  
Author(s):  
Renato Tozzoli ◽  
Marcello Bagnasco ◽  
Danilo Villalta

1999 ◽  
Vol 45 (3) ◽  
pp. 407-409 ◽  
Author(s):  
Yukihiko Watanabe ◽  
Hisato Tada ◽  
Yoh Hidaka ◽  
Toru Takano ◽  
Keiko Takeoka ◽  
...  

1993 ◽  
Vol 69 (9) ◽  
pp. 997-1002
Author(s):  
Toshihiko HISAOKA ◽  
Naoko MOMOTANI ◽  
Hiroshi YOSHIMURA ◽  
Naofumi ISHIKAWA ◽  
Kunihiko ITO ◽  
...  

2019 ◽  
Vol 105 (4) ◽  
pp. e1006-e1014 ◽  
Author(s):  
George J Kahaly ◽  
Tanja Diana ◽  
Michael Kanitz ◽  
Lara Frommer ◽  
Paul D Olivo

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition). Main Outcome Measures Response versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96. Results Forty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission. Conclusions Serum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.


Sign in / Sign up

Export Citation Format

Share Document